Objective: The aim of the study was to characterize and compare insulin resistance (IR) in hepatitis C virus (HCV)-antibody (Ab)-positive and HCV-Ab-negative patients with HIV infection. Methods: This was a single-centre cross-sectional study of 1041 HIV-infected patients (373 HCV-Ab-positive; 167 with detectable plasma HCV RNA). Metabolic and anthropometric assessments were performed, including measurement of IR using the homeostasis model for assessment of insulin resistance (HOMA-IR). Results: The prevalence of IR (i.e. a HOMA-IR score ≥3.8) was significantly higher in HCV-Ab-positive than in HCV-Ab-negative patients (47.7 vs. 32.7% P < 0.0001). On multivariable linear regression analysis, the following variables were associated with HOMA-IR score, expressed as an estimate of the percentage variation (Est.): high-density lipoprotein cholesterol (per 0.3 mmol/L increase: Est.-4.1; P = 0.01), triglycerides (per 0.1mmol/L increase: Est. 0.6; P < 0.001), alcohol intake (Est. -12.4; P = 0.002), sedentary lifestyle (Est. 14.7; P < 0.001), CD4 T-cell count in the highest quartile, i.e. ≥690 cells/μL (Est. 20.7; P = 0.002), body mass index in the highest quartiles, i.e. ≥22.54 kg/m2 (Est. 30.5-44.7; P <0.001), waist-to-hip ratio in the highest quartile, i.e. >1 (Est. 30.2; P < 0.001) and HCV-Ab positivity (Est. 24.4; P < 0.001). Conclusions: Our data confirm that HCV-Ab positivity is an independent risk factor for IR. Management aimed at correcting known risk factors for IR should be implemented. © 2008 British HIV Association.

Squillace, N., Lapadula, G., Torti, C., Orlando, G., Mandalia, S., Nardini, G., et al. (2008). Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: A cross-sectional study. HIV MEDICINE, 9(3), 151-159 [10.1111/j.1468-1293.2007.00539.x].

Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: A cross-sectional study

Squillace N.
Co-primo
;
Lapadula G.
Co-primo
;
2008

Abstract

Objective: The aim of the study was to characterize and compare insulin resistance (IR) in hepatitis C virus (HCV)-antibody (Ab)-positive and HCV-Ab-negative patients with HIV infection. Methods: This was a single-centre cross-sectional study of 1041 HIV-infected patients (373 HCV-Ab-positive; 167 with detectable plasma HCV RNA). Metabolic and anthropometric assessments were performed, including measurement of IR using the homeostasis model for assessment of insulin resistance (HOMA-IR). Results: The prevalence of IR (i.e. a HOMA-IR score ≥3.8) was significantly higher in HCV-Ab-positive than in HCV-Ab-negative patients (47.7 vs. 32.7% P < 0.0001). On multivariable linear regression analysis, the following variables were associated with HOMA-IR score, expressed as an estimate of the percentage variation (Est.): high-density lipoprotein cholesterol (per 0.3 mmol/L increase: Est.-4.1; P = 0.01), triglycerides (per 0.1mmol/L increase: Est. 0.6; P < 0.001), alcohol intake (Est. -12.4; P = 0.002), sedentary lifestyle (Est. 14.7; P < 0.001), CD4 T-cell count in the highest quartile, i.e. ≥690 cells/μL (Est. 20.7; P = 0.002), body mass index in the highest quartiles, i.e. ≥22.54 kg/m2 (Est. 30.5-44.7; P <0.001), waist-to-hip ratio in the highest quartile, i.e. >1 (Est. 30.2; P < 0.001) and HCV-Ab positivity (Est. 24.4; P < 0.001). Conclusions: Our data confirm that HCV-Ab positivity is an independent risk factor for IR. Management aimed at correcting known risk factors for IR should be implemented. © 2008 British HIV Association.
Si
Articolo in rivista - Articolo scientifico
Scientifica
HCV-Ab-positive; Hepatitis C virus; HIV; Insulin resistance; Lipodystrophy; Adult; Cross-Sectional Studies; Female; HIV Infections; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Insulin Resistance; Male; Risk Factors
English
151
159
9
Squillace, N., Lapadula, G., Torti, C., Orlando, G., Mandalia, S., Nardini, G., et al. (2008). Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: A cross-sectional study. HIV MEDICINE, 9(3), 151-159 [10.1111/j.1468-1293.2007.00539.x].
Squillace, N; Lapadula, G; Torti, C; Orlando, G; Mandalia, S; Nardini, G; Beghetto, B; Costarelli, S; Guaraldi, G
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/326132
Citazioni
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 4
Social impact